SCHEMBL24944403

SCHEMBL24944403

Cn1cnc2c(-c3nc(C(N)=O)c(Nc4ccc(N5CCOCC5)cc4)nc3C(F)(F)F)cncc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EML4 Q9HC35 5/20 0.43
▸ ALK Q9UM73 5/20 0.43
▸ CCNA2 P20248 2/20 0.42
▸ CDK2 P24941 2/20 0.42
▸ AURKA O14965 1/20 0.42
▸ CDK4 P11802 1/20 0.42
▸ CCND3 P30281 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ RET P07949 4/20 0.41
▸ ROS1 P08922 4/20 0.41
▸ FLT3 P36888 4/20 0.41
▸ CCNA1 P78396 1/20 0.41
▸ STAT6 P42226 3/20 0.40
▸ SYK P43405 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ NR4A1 P22736 1/20 0.39
▸ MAPKAPK5 Q8IW41 1/20 0.39
▸ LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173706 0.93 JAK2 (0.43) CCNA2CDK2AURKACDK4CCND3
SCHEMBL30206091 0.93 JAK2 (0.43) CCNA2CDK2AURKACDK4CCND3
SCHEMBL30205765 0.89 EML4 (0.45) EML4ALKCCNA2CDK2AURKA
SCHEMBL24944729 0.89 EML4 (0.45) EML4ALKCCNA2CDK2AURKA
SCHEMBL24944959 0.89 EML4 (0.45) EML4ALKCCNA2CDK2AURKA
SCHEMBL30205764 0.89 EML4 (0.45) EML4ALKCCNA2CDK2AURKA
SCHEMBL24944972 0.88 EML4 (0.45) EML4ALKCCNA2CDK2AURKA
SCHEMBL30206232 0.88 EML4 (0.45) EML4ALKCCNA2CDK2AURKA
SCHEMBL24943791 0.88 EML4 (0.48) EML4ALKCCNA2CDK2AURKA
SCHEMBL24944770 0.87 CSF1R (0.37) EML4ALKCCNA2CDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP claimed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN claimed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO claimed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed
Send feedback